DBV Technologies S.A. (DBVT) Discusses Positive Phase III VITESSE Trial Results for Peanut Allergy Patch in Young Children Transcript [Seeking Alpha]
DBV Technologies S.A. - American Depositary Shares (DBVT)
US:NASDAQ Investor Relations:
dbv-technologies.com/en/investor-relations
Company Research
Source: Seeking Alpha
Company Participants Jonathan Neely Daniel Tassé - CEO & Director Pharis Mohideen - Chief Medical Officer Kevin Trapp - Chief Commercial Officer Conference Call Participants Samuel Slutsky - LifeSci Capital, LLC Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Sushila Hernandez Presentation Operator Welcome to the DBV Technologies Update Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Jonathan Neely. Please go ahead, sir. Jonathan Neely Thank you, operator. This afternoon, DBV Technologies issued a press release announcing positive top line results from its Phase III VITESSE clinical trial of the VIASKIN Peanut patch in children aged 4 to 7 years old. This press release is available in the Press Releases section of the DBV Technologi
Show less
Read more
Impact Snapshot
Event Time:
DBVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DBVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DBVT alerts
High impacting DBV Technologies S.A. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
DBVT
News
- DBV Technologies (NASDAQ:DBVT) had its price target raised by analysts at Citizens Jmp from $21.00 to $45.00. They now have a "market outperform" rating on the stock.MarketBeat
- DBV Technologies (NASDAQ:DBVT) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Tesla, Netflix, Lennar, DBV Technologies, Micron, and More Stock Market Movers [Barron's]Barrons
- DBV Technologies (NASDAQ:DBVT) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years [Yahoo! Finance]Yahoo! Finance
DBVT
Sec Filings
- 12/16/25 - Form 8-K
- 12/12/25 - Form SCHEDULE
- 12/8/25 - Form SCHEDULE
- DBVT's page on the SEC website